Rechercher
FR Down
langue
Bonjour, user_no_name
Live Chat

Les CFD sont des instruments complexes et sont accompagnés d’un risque élevé de pertes financières rapides en raison de l’effet de levier. 76,3 % des comptes d’investisseurs particuliers perdent de l’argent en tradant des CFD avec ce fournisseur. Vous devez déterminer si vous comprenez comment fonctionnent les CFD et si vous pouvez vous permettre de courir le risque élevé de perdre votre argent.

Close

Moderna shares jumped another 20% and the S&P 500 rallied over 3% after the US drug maker reported positive results from its early stage trials of its potential Covid-19 vaccine. The news sent risk assets higher as a vaccine would help economies get back to a true normal far quicker than any other measure. But has Moderna really got the goods?

What we know so far:

  • All 45 participants in its early stage trial developed Covid-19 antibodies
  • Each were given a 25, 100 and 250 micogram dose – 15 people in each group. For each group they received two doses, 28 days apart.
  • Two weeks after the second dose, antibodies similar to people who have recovered from the disease were found in the 25-microgram group. In the 100-microgram group antibodies ‘significantly exceeded levels’ in recovered patients. Data for the final group was not available.

“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],” Moderna chief medical officer Dr Tal Zaks said in a statement.

“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” he added.

Moderna is just one of many drug companies racing to be the first to develop a vaccine against Covid-19.

Shares in Moderna have soared this year by at least 300% to $80 by Monday’s close. It has just announced a new placing to raise $1.3bn at $76, yet shares keep rising and Wall Street still has a strong buy rating on the stock.

Needham recently upgraded its price target on the stock to $94 from $58.

“Based on these data, we believe the vaccine is likely to be found effective for prevention of infection in a Phase 3 trial,” said Needham analyst Alan Carr. “We expect Moderna to have meaningful supply by 4Q20. We have therefore added an mRNA-1273 revenue stream to our model and are raising our price target to $94.”

Les dernières actualités

Treasury yields, dollar pull back after higher-than-expected CPI reading triggers rally

Jeudi, 12 Septembre 2024

Indices

Semaine à venir : La Réserve fédérale s’apprête à réduire ses taux, mais de combien ?

Trump-Harris debate, iPhone 16 launch, and ECB meeting in focus this week

Jeudi, 5 Septembre 2024

Indices

Semaine à venir : Lancement de l'iPhone 16, débat Trump-Harris, réunion de la BCE

Markets look to key US jobs report after Labor Day

Jeudi, 29 Aout 2024

Indices

Semaine à venir : Après la fête du travail aux États-Unis, les marchés se tournent vers les données clés de l'emploi

Samedi, 24 Aout 2024

Indices

Semaine à venir : Les marchés attendent les résultats de Nvidia

Live Chat